<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE- chlordiazepoxide and amitriptyline hydrochloride tablet, film coated </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_dc3bdafd-d09a-400a-99a1-8642d4ab8c97"></a><a name="section-1"></a><p></p>
<h1>Suicidality and Antidepressant Drugs</h1>
<p class="First"><span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of chlordiazepoxide and amitriptyline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Chlordiazepoxide and amitriptyline is not approved for use in pediatric patients. (See <a href="#i4i_section_id_5c039b2e-5962-4085-b17a-206928fdf4ec">WARNINGS: Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a>, <a href="#i4i_info_patients_id_a9d820ca-87e0-4cb8-b396-f0093fc7e57f">PRECAUTIONS: Information for Patients</a> and <a href="#i4i_pediatric_use_id_11b35153-c7ec-470d-8550-809a87fe5645">PRECAUTIONS: Pediatric Use</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_742ae541-41c9-43cd-bf6a-605b2439bf3c"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP combine for oral administration, chlordiazepoxide, an agent for the relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> and <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, and amitriptyline, an antidepressant.</p>
<p>Chlordiazepoxide, USP is a benzodiazepine with the formula 7-chloro-2-(methylamino)-5-phenyl-3<span class="Italics">H</span>-1,4-benzodiazepine-4-oxide. It is a slightly yellow crystalline material and is insoluble in water. The molecular weight is 299.76. Its structural formula is:</p>
<div class="Figure">
<a name="id471"></a><img alt="Chlordiazepoxide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a756f2-ac77-451c-a19a-08896d73b15c&amp;name=877c08a0-9a60-4639-9bc4-f02b511a5517-01.jpg">
</div>
<p>Amitriptyline, USP is a dibenzocycloheptadiene derivative. The formula is 10,11-dihydro-<span class="Italics">N,N</span>-dimethyl-5<span class="Italics">H</span>-dibenzo[a,d]cycloheptene-Δ<span class="Sup">5</span>,γ-propylamine hydrochloride. It is a white or practically white crystalline compound that is freely soluble in water. The molecular weight is 313.87. Its structural formula is:</p>
<div class="Figure">
<a name="id476"></a><img alt="Amitriptyline Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a756f2-ac77-451c-a19a-08896d73b15c&amp;name=877c08a0-9a60-4639-9bc4-f02b511a5517-02.jpg">
</div>
<p>Each tablet for oral administration contains:</p>
<p>5 mg of chlordiazepoxide and 12.5 mg of amitriptyline (as the hydrochloride salt)</p>
<p>or</p>
<p>10 mg of chlordiazepoxide and 25 mg of amitriptyline (as the hydrochloride salt) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch (corn), sodium lauryl sulfate, and titanium dioxide.</p>
<p>In addition, the 5 mg/12.5 mg product contains D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake and FD&amp;C Yellow No. 6 Aluminum Lake and the 10 mg/25 mg product contains calcium sulfate and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_73f0cd3a-b815-4592-ad7b-f3f614e7bd84"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Both components of Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP exert their action in the central nervous system. Extensive studies with chlordiazepoxide in many animal species suggest action in the limbic system. Recent evidence indicates that the limbic system is involved in emotional response. Taming action was observed in some species. The mechanism of action of amitriptyline in man is not known, but the drug appears to interfere with the reuptake of norepinephrine into adrenergic nerve endings. This action may prolong the sympathetic activity of biogenic amines.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_de3b6575-9ef6-4009-8c62-0a5e9c80b064"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Chlordiazepoxide and amitriptyline hydrochloride is indicated for the treatment of patients with moderate to severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> associated with moderate to severe <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p>The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone.</p>
<p>Symptoms likely to respond in the first week of treatment include: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, feelings of guilt or worthlessness, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, psychic and somatic <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d9fadb71-184d-4ee7-a2a2-9e10d0a044a0"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Chlordiazepoxide and amitriptyline hydrochloride is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to either benzodiazepines or tricyclic antidepressants. It should not be given concomitantly with a monoamine oxidase inhibitor. Hyperpyretic crises, severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred in patients receiving a tricyclic antidepressant and a monoamine oxidase inhibitor simultaneously. When it is desired to replace a monoamine oxidase inhibitor with chlordiazepoxide and amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. Chlordiazepoxide and amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved.</p>
<p>This drug is contraindicated during the acute recovery phase following <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_467ff3aa-23dd-45a2-9dbe-27464da50918"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5c039b2e-5962-4085-b17a-206928fdf4ec"></a><a name="section-5.1"></a><p></p>
<h2>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.</p>
<a name="_Refid_f461ebcd-6e35-4038-9841-db97256dc"></a><table width="100%">
<caption><span>Table 1</span></caption>
<col width="28%">
<col width="72%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Age Range</span></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Drug-Placebo Difference in </span><br><span class="Bold">Number of Cases of Suicidality </span><br><span class="Bold">Per 1,000 Patients Treated</span>
</th>
</tr></thead>
<tbody>
<tr class="First"><td class="Botrule Toprule" align="center" colspan="2"><p class="First">Increases Compared to Placebo</p></td></tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">&lt; 18</p></td>
<td class="Botrule" align="center"><p class="First">14 additional cases</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">18 to 24</p></td>
<td class="Botrule" align="center"><p class="First">5 additional cases</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="2"><p class="First">Decreases Compared to Placebo</p></td></tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">25 to 64</p></td>
<td class="Botrule" align="center"><p class="First">1 fewer case</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center"><p class="First">≥ 65</p></td>
<td class="Botrule" align="center"><p class="First">6 fewer cases</p></td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.</span> Prescriptions for chlordiazepoxide and amitriptyline should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b846678a-c9d5-4d0e-9cb9-8a9268f35957"></a><a name="section-5.2"></a><p></p>
<h2>Screening Patients for Bipolar Disorder</h2>
<p class="First">A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that chlordiazepoxide and amitriptyline is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b3114221-b9bb-4c57-9bb8-be6f17d95ac2"></a><a name="section-5.3"></a><p></p>
<h2>Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">The pupillary dilation that occurs following use of many antidepressant drugs including chlordiazepoxide and amitriptyline hydrochloride may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f70108f-04a5-42ad-bb42-b84fa4ba9cd2"></a><a name="section-5.4"></a><p></p>
<h2>General</h2>
<p class="First">Because of the atropine like action of the amitriptyline component, great care should be used in treating patients with a history of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> or <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>. In patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, even average doses may precipitate an attack. Severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> may occur in patients taking tricyclic antidepressants in combination with anticholinergic type drugs.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span> should be watched closely. Tricyclic antidepressant drugs, particularly when given in high doses, have been reported to produce <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span> and prolongation of conduction time. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have been reported in patients receiving drugs of this class.</p>
<p>Because of the sedative effects of chlordiazepoxide and amitriptyline hydrochloride, patients should be cautioned about combined effects with alcohol or other CNS depressants. The additive effects may produce a harmful level of sedation and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
<p>Patients receiving chlordiazepoxide and amitriptyline hydrochloride should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2882f62f-8ff5-451d-bed4-d6572fa1a787"></a><a name="section-5.5"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">Safe use of chlordiazepoxide and amitriptyline hydrochloride during pregnancy and lactation has not been established. Because of the chlordiazepoxide component, please note the following:</p>
<dl>
<dt> </dt>
<dd><span class="Bold">An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.</span></dd>
</dl>
<p>Withdrawal symptoms of the barbiturate type have occurred after discontinuation of benzodiazepines. (See <a href="#i4i_abuse_dependence_id_48a551af-4966-4903-ba09-73f8002f04e1">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_58df1dd8-de55-46c2-8d17-b30acb759bce"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_5d7bc499-7419-4410-93e9-9d6175cc6d31"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Use with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Close supervision is required when chlordiazepoxide and amitriptyline hydrochloride is given to hyperthyroid patients or those on thyroid medication.</p>
<p>The usual precautions should be observed when treating patients with impaired renal or hepatic function.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> should not have easy access to large quantities of the drug. The possibility of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> in depressed patients remains until significant remission occurs.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_a9d820ca-87e0-4cb8-b396-f0093fc7e57f"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with chlordiazepoxide and amitriptyline and should counsel them in its appropriate use. A patient Medication Guide about "Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illness and Suicidal Thoughts or Actions" is available for chlordiazepoxide and amitriptyline. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking chlordiazepoxide and amitriptyline.</p>
<p>Patients should be advised that taking chlordiazepoxide and amitriptyline hydrochloride can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Pre-existing <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is almost always open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> because angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, when diagnosed, can be treated definitively with iridectomy. Open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> is not a risk factor for <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> procedure (e.g., iridectomy), if they are susceptible.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba8f8e62-9d39-4446-91d8-1569639799f1"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</span></span></h3>
<p class="First">Patients, their families and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day to day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.</p>
<p>To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_bbdd9c27-2bc8-4dbc-b847-8995b8cba14b"></a><a name="section-6.3"></a><p></p>
<h2>Essential Laboratory Tests</h2>
<p class="First">Patients on prolonged treatment should have periodic liver function tests and blood counts.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_da40ef05-1fde-49e1-87dc-e641cb98a35f"></a><a name="section-6.4"></a><p></p>
<h2>Drug and Treatment Interactions</h2>
<p class="First">Because of its amitriptyline component, chlordiazepoxide and amitriptyline hydrochloride may block the antihypertensive action of guanethidine or compounds with a similar mechanism of action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c72b964-6c8d-422f-99c9-180b870f4c24"></a><a name="section-6.5"></a><p></p>
<h2>Drugs Metabolized by P450 2D6</h2>
<p class="First">The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</p>
<p>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</p>
<p>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</p>
<p>The effects of concomitant administration of chlordiazepoxide and amitriptyline hydrochloride and other psychotropic drugs have not been evaluated. Sedative effects may be additive.</p>
<p>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants and benzodiazepines, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.</p>
<p>The drug should be discontinued several days before elective surgery.</p>
<p>Concurrent administration of ECT and chlordiazepoxide and amitriptyline hydrochloride should be limited to those patients for whom it is essential.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_184fcc69-077f-4e25-92b1-be27d148ab2a"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">See <a href="#i4i_warnings_id_467ff3aa-23dd-45a2-9dbe-27464da50918">WARNINGS</a>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_07399107-7ca6-44a2-aa2a-4f802b30771d"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug, since many drugs are excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_11b35153-c7ec-470d-8550-809a87fe5645"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in the pediatric population have not been established (see <a href="#id_dc3bdafd-d09a-400a-99a1-8642d4ab8c97">BOX WARNING</a> and <a href="#i4i_section_id_5c039b2e-5962-4085-b17a-206928fdf4ec">WARNINGS: Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a>).</p>
<p>Anyone considering the use of chlordiazepoxide and amitriptyline in a child or adolescent must balance the potential risks with the clinical need.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_995065b1-1d16-40ef-b217-b82ec37420d3"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In elderly and debilitated patients it is recommended that dosage be limited to the smallest effective amount to preclude the development of <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, over sedation, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or anticholinergic effects.</p>
<p>Of the total number of subjects in clinical studies of chlordiazepoxide and amitriptyline hydrochloride tablets, 74 individuals were 65 years and older. An additional 34 subjects were between 60 and 69 years of age. No overall differences in safety and effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>The active ingredients in chlordiazepoxide and amitriptyline hydrochloride tablets are known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over sedation in the elderly; elderly patients generally should be started on low doses of chlordiazepoxide and amitriptyline hydrochloride tablets and observed closely.</p>
<p>Clinical studies of chlordiazepoxide and amitriptyline hydrochloride tablets did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_dfcd14bf-a787-46e7-a57c-8b5cb1576858"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions to chlordiazepoxide and amitriptyline hydrochloride are those associated with the use of either component alone. Most frequently reported were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>. Other side effects occurring less commonly included <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>. Many symptoms common to the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive state</span>, such as <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, have been reported as side effects of treatment with both chlordiazepoxide and amitriptyline hydrochloride tablets and amitriptyline tablets.</p>
<p><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and hepatic dysfunction of uncertain etiology have also been observed rarely with chlordiazepoxide and amitriptyline hydrochloride. When treatment with chlordiazepoxide and amitriptyline hydrochloride is prolonged, periodic blood counts and liver function tests are advisable.</p>
<p><span class="Bold">Note:</span> Included in the listing which follows are adverse reactions which have not been reported with chlordiazepoxide and amitriptyline hydrochloride. However, they are included because they have been reported during therapy with one or both of the components or closely related drugs.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">poor concentration</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> and increased or decreased libido</p>
<p><span class="Bold">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of the extremities, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, changes in EEG patterns</p>
<p><span class="Bold">Anticholinergic:</span> disturbance of accommodation, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, dilatation of urinary tract</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, photosensitization, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of face and tongue, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> including <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, peculiar taste, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, black tongue</p>
<p><span class="Bold">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> in the male, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> and minor menstrual irregularities in the female, elevation and lowering of blood sugar levels, and syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH</span> (antidiuretic hormone) secretion</p>
<p><span class="Bold">Other:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss, increased perspiration, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4152183" conceptname="Parotid swelling">parotid swelling</span></p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_48a551af-4966-4903-ba09-73f8002f04e1"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), have occurred following abrupt discontinuance of chlordiazepoxide. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Withdrawal symptoms (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>) have also been reported in association with abrupt amitriptyline discontinuation. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving chlordiazepoxide or other psychotropic agents because of the predisposition of such patients to <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f71aef12-b99d-4679-9246-56d0d526e76e"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE*</h1>
<p class="First">*Poisindex<span class="Sup">®</span> Toxicologic Management. Topic: Antidepressants, Tricyclic. <span class="Italics">Micromedex Inc.</span> Vol. 85.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> may occur from overdosage with this class of drugs. Multiple drug ingestion (including alcohol) is common in deliberate tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. As the management is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity develop rapidly after tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; therefore, hospital monitoring is required as soon as possible.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_edf4b3e9-1323-4cbb-855f-77a64764cce9"></a><a name="section-9.1"></a><p></p>
<h2>Manifestations</h2>
<p class="First">Critical manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, including <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity.</p>
<p>Other signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, disturbed concentration, transient <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> or any of the symptoms listed under <a href="#i4i_adverse_effects_id_dfcd14bf-a787-46e7-a57c-8b5cb1576858">ADVERSE REACTIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0f2bb7b-f707-41e5-9c62-e623ce6b1384"></a><a name="section-9.2"></a><p></p>
<h2>Management</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7047f28-b90e-46d1-a43d-9636c8414095"></a><a name="section-9.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">General</span></span></h3>
<p class="First">Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or conduction blocks, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. <span class="Italics">There are case reports of patients succumbing to fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> late after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; these patients had clinical evidence of significant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> prior to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and most received inadequate gastrointestinal decontamination.</span> Monitoring of plasma drug levels should not guide management of the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6418e7b7-a9eb-4681-a45d-c330519e4dbc"></a><a name="section-9.2.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Gastrointestinal Decontamination</span></span></h3>
<p class="First">All patients suspected of tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94278d92-bb79-490d-956c-3cba7e762f21"></a><a name="section-9.2.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Cardiovascular</span></span></h3>
<p class="First">A maximal limb lead QRS duration of ≥ 0.10 seconds may be the best indication of the severity of the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Serum alkalinization, to a pH of 7.45 to 7.56, using intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (as needed) should be instituted for patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> and/or QRS widening. A pH &gt; 7.60 or a pCO<span class="Sub">2</span> &lt; 20 mm Hg is undesirable. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Dysrhythmias</span> unresponsive to sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> therapy/<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide and procainamide).</p>
<p>In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions and forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> generally have been reported as ineffective in tricyclic antidepressant <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_161bdb6f-ac3f-403d-8b8b-6fec4c2b192e"></a><a name="section-9.2.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">CNS</span></span></h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, early intubation is advised because of the potential for abrupt deterioration. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). <span class="Italics">Physostigmine is not recommended except to treat life threatening symptoms that have been unresponsive to other therapies,</span> and then only in consultation with a poison control center.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_388cfb5a-4453-4f66-acbe-133ca50f5e8d"></a><a name="section-9.2.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">Psychiatric Follow-up</span></span></h3>
<p class="First">Since overdosage is often deliberate, patients may attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> by other means during the recovery phase. Psychiatric referral may be appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a97c610c-f21c-4502-a885-a3a9b4a8df45"></a><a name="section-9.2.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pediatric Management</span></span></h3>
<p class="First">The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c16d17e-33f4-447d-b4cd-7c6442c64b35"></a><a name="section-9.2.7"></a><p></p>
<h3><span class="Bold"><span class="Italics">Chlordiazepoxide Overdosage</span></span></h3>
<p class="First">Manifestations of benzodiazepine overdosage include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">diminished reflexes</span>. Dialysis is of limited value. There have been occasional reports of excitation in patients following benzodiazepine overdosage; if this occurs, barbiturates should not be used. Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see <a href="#i4i_abuse_dependence_id_48a551af-4966-4903-ba09-73f8002f04e1">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>). Since chlordiazepoxide and amitriptyline hydrochloride contains amitriptyline, it is important to note that use of the benzodiazepine antagonist flumazenil is contraindicated in patients who are showing signs of serious cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d5d04727-22c1-48bc-bb5a-d1df7a31f266"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Optimum dosage varies with the severity of the symptoms and the response of the individual patient. When a satisfactory response is obtained, dosage should be reduced to the smallest amount needed to maintain the remission. The larger portion of the total daily dose may be taken at bedtime. In some patients, a single dose at bedtime may be sufficient. In general, lower dosages are recommended for elderly patients.</p>
<p>Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP 10 mg/25 mg are recommended in an initial dosage of 3 or 4 tablets daily in divided doses; this may be increased to 6 tablets daily as required. Some patients respond to smaller doses and can be maintained on 2 tablets daily.</p>
<p>Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP 5 mg/12.5 mg in an initial dosage of 3 or 4 tablets daily in divided doses may be satisfactory in patients who do not tolerate higher doses.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f5afba83-dd81-4274-a118-4cd1eb11cb1c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP are available containing 5 mg of chlordiazepoxide, USP and 12.5 mg of amitriptyline, USP (as the hydrochloride salt) or 10 mg of chlordiazepoxide, USP and 25 mg of amitriptyline, USP (as the hydrochloride salt).</p>
<p>The 5 mg/12.5 mg tablets are green film-coated, round, unscored tablets debossed with <span class="Bold">MYLAN</span> on one side of the tablet and <span class="Bold">211</span> on the other side. They are available as follows:</p>
<p>NDC 0378-0211-01<br>bottles of 100 tablets</p>
<p>NDC 0378-0211-05<br>bottles of 500 tablets</p>
<p>The 10 mg/25 mg tablets are white film-coated, round, unscored tablets debossed with <span class="Bold">MYLAN</span> on one side of the tablet and <span class="Bold">277</span> on the other side. They are available as follows:</p>
<p>NDC 0378-0277-01<br>bottles of 100 tablets</p>
<p>NDC 0378-0277-05<br>bottles of 500 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Medication Guide with each prescription.</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_b1d9c6ec-94a5-405c-9639-c13795a2bd02"></a><a name="section-12"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions</span></p>
<p>Read the Medication Guide that comes with your or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <span class="Bold">Talk to your, or your family member's, healthcare provider about:</span></p>
<dl>
<dt>•</dt>
<dd>all risks and benefits of treatment with antidepressant medicines</dd>
<dt>•</dt>
<dd>all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness</dd>
</dl>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions?</span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions.</span> These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.  </dd>
<dt>3.</dt>
<dd>
<span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span><dl>
<dt>•</dt>
<dd>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.</dd>
<dt>•</dt>
<dd>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.</dd>
<dt>•</dt>
<dd>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.</dd>
</dl>
</dd>
<dt> </dt>
<dd>
<span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span><dl>
<dt>•</dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</dd>
<dt>•</dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></dd>
<dt>•</dt>
<dd>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></dd>
<dt>•</dt>
<dd>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
<dt>•</dt>
<dd>acting aggressive, being angry, or violent</dd>
<dt>•</dt>
<dd>acting on dangerous impulses</dd>
<dt>•</dt>
<dd>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</dd>
<dt>•</dt>
<dd>other unusual changes in behavior or mood</dd>
<dt>•</dt>
<dd>
<span class="Bold">Visual problems:</span> <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, changes in vision, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in or around the eye</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What else do I need to know about antidepressant medicines?</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider.</span> Stopping an antidepressant medicine suddenly can cause other symptoms.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Visual problems:</span> Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses.</span> It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your child's healthcare provider for more information.</dd>
</dl>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV  26505  U.S.A.</p>
<p>REVISED DECEMBER 2014<br>CDAM:R15mmh</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ebf45b8f-43ca-4692-bcf1-61e97f529657"></a><a name="section-13"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 5 mg/12.5 mg</span></p>
<p><span class="Bold">NDC 0378-0211-01</span></p>
<p><span class="Bold">Chlordiazepoxide <br>and <br>Amitriptyline HCl <br>Tablets, USP</span><br><span class="Bold">CIV</span><br><span class="Bold">5 mg/</span><br><span class="Bold">12.5 mg*</span></p>
<p><span class="Bold">Rx only</span>     <span class="Bold">100 Tablets</span></p>
<p>*Each film-coated tablet contains <br>5 mg of chlordiazepoxide, USP <br>and 12.5 mg of amitriptyline, USP<br>(as the hydrochloride salt).</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See <br>accompanying prescribing <br>information.</p>
<p><span class="Bold">PHARMACIST: Dispense the<br>accompanying Medication<br>Guide to each patient.</span></p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM0211A12</span></p>
<div class="Figure">
<a name="id997"></a><img alt="Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP 5 mg/12.5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a756f2-ac77-451c-a19a-08896d73b15c&amp;name=877c08a0-9a60-4639-9bc4-f02b511a5517-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ef0492dc-0679-455b-b09b-c8c7fb47a384"></a><a name="section-14"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 10 mg/25 mg</span></p>
<p><span class="Bold">NDC 0378-0277-01</span></p>
<p><span class="Bold">Chlordiazepoxide</span> <br><span class="Bold">and</span><br><span class="Bold">Amitriptyline HCl</span><br><span class="Bold">Tablets, USP</span><br><span class="Bold">CIV</span><br><span class="Bold">10 mg/</span><br><span class="Bold">25 mg*</span></p>
<p><span class="Bold">Rx only</span>     <span class="Bold">100 Tablets</span></p>
<p>*Each film-coated tablet contains <br>10 mg of chlordiazepoxide, USP <br>and 25 mg of amitriptyline, USP<br>(as the hydrochloride salt).</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See <br>accompanying prescribing <br>information.</p>
<p><span class="Bold">PHARMACIST: Dispense the<br>accompanying Medication<br>Guide to each patient.</span></p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM0277A12</span></p>
<div class="Figure">
<a name="id1068"></a><img alt="Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, USP 10 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=66a756f2-ac77-451c-a19a-08896d73b15c&amp;name=877c08a0-9a60-4639-9bc4-f02b511a5517-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">chlordiazepoxide and amitriptyline hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHLORDIAZEPOXIDE</strong> (CHLORDIAZEPOXIDE) </td>
<td class="formItem">CHLORDIAZEPOXIDE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMITRIPTYLINE HYDROCHLORIDE</strong> (AMITRIPTYLINE) </td>
<td class="formItem">AMITRIPTYLINE HYDROCHLORIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;211</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0211-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-0211-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071297</td>
<td class="formItem">12/10/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">chlordiazepoxide and amitriptyline hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0277</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHLORDIAZEPOXIDE</strong> (CHLORDIAZEPOXIDE) </td>
<td class="formItem">CHLORDIAZEPOXIDE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>AMITRIPTYLINE HYDROCHLORIDE</strong> (AMITRIPTYLINE) </td>
<td class="formItem">AMITRIPTYLINE HYDROCHLORIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;277</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0277-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-0277-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071297</td>
<td class="formItem">12/10/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>caee5f59-f0ec-482b-8d82-8436a4686374</div>
<div>Set id: 66a756f2-ac77-451c-a19a-08896d73b15c</div>
<div>Version: 7</div>
<div>Effective Time: 20141223</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
